Seeking Alpha

Buy the recent weakness in Endo Pharmaceuticals (ENDP +0.5%) sparked by yesterday's FDA's denial...

Buy the recent weakness in Endo Pharmaceuticals (ENDP +0.5%) sparked by yesterday's FDA's denial of ViroPharma's Vancocin citizen petition, Cantor Fitzgerald says. The firm notes heightened investor anxiety around approval of ENDP's generic Liboderm amid the VPHM news, but it believes "Vancocin is not a good proxy for Liboderm." (also)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs